CME; MDD, residual symptoms, vortioxetine

Overview
This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Receives royalties: American Psychiatric Publishing, Cambridge University Press
Consulting Fees: Abbvie, Alkermes, Axsome, BioXcel, Intracellular Therapies, Neurelis, Neumora, Otsuka, Sage Pharmaceuticals Sunovion, Supernu
Manpreet Kaur Singh, MD, MS
Professor of Psychiatry and Behavioral Sciences
University of California, Davis
Davis, CA
Dr. Singh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: NIH; PCori; BBRF
Receives Royalties: American Psychiatric Association Publishing, Thrive Global
Consulting Fees: AbbVie Inc, Alkermes, Alto Neuroscience, Boehringer-Ingelheim, Johnson and Johnson, Karuna Therapeutics, Inc., Intra-Cellular Therapeutics, Inc, Neumora, Skyland Trail
Honoraria: American Academy of Child and Adolescent Psychiatry
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Elena Haemin Go has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Rosanne Strauss, PharmD, MBA, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Emphasize the importance of routine assessment for residual symptoms of major depressive disorder (MDD) using standardized tools, even in patients who appear to be in remission, to ensure comprehensive management
- Tailor treatment plans for MDD based on the patient's unique symptom profile
- Differentiate between pharmacological and non-pharmacological interventions that target residual symptoms of MDD
- Develop strategies to enhance patient engagement, education, and adherence to MDD treatment
- Improve ability to adjust treatment strategies for patients with MDD who exhibit treatment resistance early in the treatment process
Target Audience
This activity has been designed to meet the educational needs of psychiatrists and psychiatric nurse practitioners (PMHNPs), as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with major depressive disorder, particularly those with persistent residual symptoms.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare.

Global Learning Collaborative (GLC) designates this MinuteCE activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until July 15, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.025 CEUs of pharmacy contact hours.¹

The Universal Activity Number for this program is JA0006235-0000-24-088-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)

It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals USA, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 07/15/2024
Expiration Date: 07/15/2025